Last reviewed · How we verify
NCT06794502
Butterfly Pea Flower (Clitoria Ternatea) for Adjuvant TB Treatment
EARLY_PHASE1 trial testing Herbal medicine in Tuberculosis (TB) in 28 participants. Completed in 31 August 2024.
30 June 2024
Quick facts
| Lead sponsor | Universitas Muhammadiyah Semarang |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 28 |
| Start date | 14 March 2024 |
| Primary completion | 30 June 2024 |
| Estimated completion | 31 August 2024 |
| Sites | 2 locations across Indonesia |
Drugs / interventions tested
- Herbal medicine — full drug profile →
- Tuberculosis (TB) treatment
Conditions studied
- Tuberculosis (TB) — all drugs for Tuberculosis (TB) →
- Tuberculosis Treatment Effectiveness — all drugs for Tuberculosis Treatment Effectiveness →
Sponsor
Universitas Muhammadiyah Semarang
Who can join
Adults 18 to 69, any sex, with Tuberculosis (TB) or Tuberculosis Treatment Effectiveness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if butterfly pea flowers (Clitoria ternatea) decocta extract works to treat as adjuvant therapy for tuberculosis in adults. It will also learn about the safety of butterfly pea flowers decocta extract. The main questions it aims to answer are: * Does butterfly pea flower extract as an adjunct TB drug therapy drug affect the profiles of interferon gamma and interleukin-10 of people with tuberculosis? * Does butterfly pea flower extract as an adjunct TB drug therapy drug affect the hematology profiles of people with tuberculosis? * Does butterfly pea flower extract as an adjunct TB drug therapy drug affect the clinical symptoms and acid-fast bacilli microscopic analysis of people with tuberculosis? * What medical problems do participants have when taking butterfly pea flower decocta extracts? Researchers will compare butterfly pea flower extract as an adjunct TB drug therapy to monotherapy TB drugs to see if adjuvant butterfly pea flowers extract works to treat tuberculosis infection in 2-month initiation phase therapy. Participants will: * Take drug butterfly pea flower extract plus TB regimen drugs consisting of rifampicin, isoniazid, pyrazinamide, and ethambutol or monotherapy TB regimen drugs only every day for 2 months * Willing to undergo treatment monitoring and visit the clinic once every 2 weeks for checkups and tests * Keep a diary of their symptoms and the number of times they use a butterfly pea flower decocta extract
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06794502
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Herbal medicine
Trials testing the same drug.
- NCT05067998 — The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature · recruiting
- NCT04566939 — A Long Term Follow-Up of Rotator Cuff Tear Patients Treated With Integrated Complementary and Alternative Medicine · completed
- NCT03959098 — Effectiveness and Safety of Korean Medicine Treatment for Cervical Disc Herniation · active not recruiting
- NCT03858556 — Effect of Chuna Manipulation Therapy on Gait in Patients With Lumbar Disc Herniation · withdrawn
- NCT03838952 — The Efficacy of Traditional Chinese Herbal Medicine for Dementia · NA · unknown
Other recruiting trials for Tuberculosis (TB)
Currently open trials in the same condition.
- NCT06963606 — Effectiveness of Computer-Aided Detection Chest X-Ray Screening for Improving Tuberculosis Diagnostic Yield in Chinese P · NA · recruiting
- NCT07178860 — Respiratory Health and Wellbeing Post Pulmonary Tuberculosis · recruiting
- NCT06909799 — A Confirmatory Trial of Adjunctive NAC to Prevent Post Tuberculosis Lung Disease · NA · recruiting
- NCT06997367 — Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV16 · Phase 2 · active not recruiting
- NCT06916962 — Examining Psycho-Socioeconomic Linkages in TB Care: The UPLIFT Trial · NA · recruiting
Other Universitas Muhammadiyah Semarang trials
Trials by the same sponsor.
- NCT04439981 — Curcuma Extract Beneficial for Muscle Damage · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06794502 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitas Muhammadiyah Semarang
- Last refreshed: 27 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06794502.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing